van Dalen and colleagues (10) studied 1,909 community-dwelling individuals aged 70–78 years who participated in the Prevention of Dementia by Intensive Vascular Care (PreDIVA) trial in the Netherlands from 2006 to 2009 with 6–8 years of follow-up, and showed, in fact, that angiotensin-II stimulating antihypertensive users had a 45% lower incident dementia rate (hazard ratio: 0.55; 95% CI: 0.34–0.89) than those angiotensin-II inhibiting antihypertensive users. This evidence concerns the gene AGT and dementia.